Contrast-induced acute kidney injury

1. GLP-1 receptor agonists lower the risk of contrast-induced acute kidney injury in humans (OR 0.290, 95% CI 0.119-0.708).

   Humansin patients with T2DM undergoing coronary angiography or PCI

   Effects of GLP-1 receptor agonists on the incidence of contrast-induced acute kidney injury in patients with Type 2 diabetes mellitus undergoing coronary interventions

   Frontiers in endocrinology·27 Aug 2026

More on GLP-1 receptor agonists

1. SGLT2 inhibitors lower the risk of contrast-induced acute kidney injury in humans (OR 0.64, 95% CI 0.47–0.87).

   “and significantly reduced CI-AKI (OR 0.64, 95% CI 0.47–0.87)”

   Human trialperioperative

   Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Perioperative Management: A Systematic Review and Meta-Analysis

   Research Square·23 Aug 2026Preprint

More on SGLT2 inhibitors

1. Dapagliflozin lowers the risk of contrast-induced acute kidney injury in humans (6/161 [3.7%] vs. 23/161 [14.3%]).

   Human trialdiabetic patients scheduled for CCTA10 mg once dailybeginning 3 days before CCTA through 72-h post-CCTAn = 322

   Short-Term Peri-Procedural Dapagliflozin for Prevention of Contrast-Induced Acute Kidney Injury in Diabetic Patients Undergoing Coronary Computed Tomographic Angiography: A Prospective Randomized Double-Blind Placebo-Controlled Study

   Cardiorenal medicine·20 Aug 2026

More on Dapagliflozin